Regenerative MedicineConfirmed
The First Huntington's Patient Received Neural Stem Cells in a First-in-Human Trial
UCI Health treated the first patient in REGEN4HD, moving hNSC-01 from preclinical promise into human safety testing for Huntington's disease.
Why now
First-patient dosing moves a neural stem cell strategy for Huntington's disease from preclinical story to monitored human safety trial.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 27, 2026
